Literature DB >> 15266205

Hereditary hemorrhagic telangiectasia: an overview of diagnosis and management in the molecular era for clinicians.

Pinar Bayrak-Toydemir1, Rong Mao, Susan Lewin, Jamie McDonald.   

Abstract

Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome) is a relatively common, underdiagnosed autosomal-dominant disorder of arteriovenous malformations and telangiectases. DNA testing for hereditary hemorrhagic telangiectasia has recently become available in North America, making presymptomatic screening available to relatives with a positive molecular diagnosis. This now enables practitioners to prevent catastrophic complications of undiagnosed pulmonary and CNS arteriovenous malformations and eliminates the need to radiographically screen all at-risk relatives shown to be unaffected by molecular testing. We review the clinical aspects of hereditary hemorrhagic telangiectasia, describe the indications, benefits, and limitations of molecular diagnostic testing for hereditary hemorrhagic telangiectasia, and provide a molecular genetics summary to facilitate genetic counseling before and after DNA testing for this complex disorder.

Entities:  

Mesh:

Year:  2004        PMID: 15266205     DOI: 10.1097/01.gim.0000132689.25644.7c

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  37 in total

1.  An evaluation of the severity and progression of epistaxis in hereditary hemorrhagic telangiectasia 1 versus hereditary hemorrhagic telangiectasia 2.

Authors:  Benjamin N Hunter; Benjamin H Timmins; Jamie McDonald; Kevin J Whitehead; P Daniel Ward; Kevin F Wilson
Journal:  Laryngoscope       Date:  2015-09-15       Impact factor: 3.325

Review 2.  Hereditary hemorrhagic telangiectasia.

Authors:  Anne Grand'Maison
Journal:  CMAJ       Date:  2009-04-14       Impact factor: 8.262

3.  Combined juvenile polyposis and hereditary hemorrhagic telangiectasia.

Authors:  Jane-Claire B Williams; J Kent Hamilton; Michelle Shiller; Laurice Fischer; Gregory Deprisco; C Richard Boland
Journal:  Proc (Bayl Univ Med Cent)       Date:  2012-10

4.  Treatment of severe refractory epistaxis in hereditary hemorrhagic telangiectasia using a two-flap nasal closure method.

Authors:  Benjamin H Timmins; Benjamin N Hunter; Kevin F Wilson; P Daniel Ward
Journal:  Int Forum Allergy Rhinol       Date:  2016-01-11       Impact factor: 3.858

Review 5.  Signs and genetics of rare cancer syndromes with gastroenterological features.

Authors:  William Bruno; Giuseppe Fornarini; Paola Ghiorzo
Journal:  World J Gastroenterol       Date:  2015-08-14       Impact factor: 5.742

Review 6.  Embolisation for pulmonary arteriovenous malformation.

Authors:  Charlie C-T Hsu; Gigi Nc Kwan; Hannah Evans-Barns; Mieke L van Driel
Journal:  Cochrane Database Syst Rev       Date:  2018-01-04

Review 7.  Endoglin in liver fibrogenesis: Bridging basic science and clinical practice.

Authors:  Steffen K Meurer; Muhammad Alsamman; David Scholten; Ralf Weiskirchen
Journal:  World J Biol Chem       Date:  2014-05-26

8.  Juvenile polyposis, hereditary hemorrhagic telangiectasia, and early onset colorectal cancer in patients with SMAD4 mutation.

Authors:  Frank Schwenter; Marie E Faughnan; Abigail B Gradinger; Terri Berk; Robert Gryfe; Aaron Pollett; Zane Cohen; Steven Gallinger; Carol Durno
Journal:  J Gastroenterol       Date:  2012-02-14       Impact factor: 7.527

9.  High proportion of large genomic deletions and a genotype phenotype update in 80 unrelated families with juvenile polyposis syndrome.

Authors:  S Aretz; D Stienen; S Uhlhaas; M Stolte; M M Entius; S Loff; W Back; A Kaufmann; K-M Keller; S H Blaas; R Siebert; S Vogt; S Spranger; E Holinski-Feder; L Sunde; P Propping; W Friedl
Journal:  J Med Genet       Date:  2007-09-14       Impact factor: 6.318

10.  Multiple sequence variants in hereditary hemorrhagic telangiectasia cases: illustration of complexity in molecular diagnostic interpretation.

Authors:  Jamie McDonald; Friederike Gedge; Allene Burdette; James Carlisle; Changkuoth Jock Bukjiok; Michelle Fox; Pinar Bayrak-Toydemir
Journal:  J Mol Diagn       Date:  2009-09-18       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.